Biohaven Pharma (BHVN) Misses Q4 EPS by 11c

Biohaven Pharma (NYSE: BHVN) reported Q4 EPS of ($1.71), $0.11 worse than the analyst estimate of ($1.60).

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• PreveCeutical closes second tranche of private placement for $245,000
• Invesco Mortgage Capital declares $0.12 monthly dividend for June 2026